AU Patent

AU2011251747B2 — Extended release formulations of desvenlafaxine base

Assigned to Alembic Ltd · Expires 2014-08-07 · 12y expired

What this patent protects

An extended release pharmaceutical composition comprising micronized desvenlafaxine base, at least one pH modifier and at least one release controlling agent and its process for preparation. An extended release monolithic tablet is also provided. Further extended release tablets …

USPTO Abstract

An extended release pharmaceutical composition comprising micronized desvenlafaxine base, at least one pH modifier and at least one release controlling agent and its process for preparation. An extended release monolithic tablet is also provided. Further extended release tablets comprising micronized desvenlafaxine base; at least one pH modifier; at least one release controlling agent; and at least one binder; wherein, the proportion of binder in the tablet is greater than about 3.0% of the total weight of the tablet and wherein, the pH modifier is present in a proportion of more than about 15 parts for each of the 100 parts of the desvenlafaxine base is also provided. Also provided is process for preparation of extended release tablet.

Drugs covered by this patent

Patent Metadata

Patent number
AU2011251747B2
Jurisdiction
AU
Classification
—
Expires
2014-08-07
Drug substance claim
No
Drug product claim
No
Assignee
Alembic Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.